- Home
- GSHD vs GHRS Comparison
GSHD vs GHRS Comparison
Compare GSHD & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GSHD | GHRS |
|---|---|---|
| Founded | 2003 | 2018 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 947.2M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GSHD | GHRS |
|---|---|---|
| Price | $40.59 | $21.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $72.50 | $41.38 |
| AVG Volume (30 Days) | ★ 381.2K | 252.6K |
| Earning Date | 04-22-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $365,304,000.00 | N/A |
| Revenue This Year | $16.40 | N/A |
| Revenue Next Year | $18.53 | N/A |
| P/E Ratio | $40.72 | ★ N/A |
| Revenue Growth | ★ 16.15 | N/A |
| 52 Week Low | $39.64 | $9.52 |
| 52 Week High | $114.76 | $24.66 |
Technical Indicators
Market Signals| Indicator | GSHD | GHRS |
|---|---|---|
| Relative Strength Index (RSI) | 39.34 | 62.50 |
| Support Level | N/A | $12.41 |
| Resistance Level | $46.40 | $24.66 |
| Average True Range (ATR) | 2.86 | 1.48 |
| MACD | -0.51 | 0.08 |
| Stochastic Oscillator | 3.26 | 68.22 |
Price Performance
Historical ComparisonAbout GSHD Goosehead Insurance Inc.
Goosehead Insurance Inc operates as an insurance agency. Its insurance products consist of homeowner's insurance; auto insurance; other personal lines products including flood, wind and earthquake insurance; excess liability or umbrella insurance; specialty lines insurance (motorcycle, recreational vehicle and other insurance); commercial lines insurance (general liability, property, and auto insurance for small businesses); and life insurance. Geographically, it operates in Texas, California, Illinois, Florida, and other regions. The company is has a single reportable segment: insurance distribution.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.